Literature DB >> 30815978

The impact of therapy on the risk of asthma in type 2 diabetes.

Louise H Rayner1,2, Andrew Mcgovern1, Julian Sherlock1, Piers Gatenby1,2, Ana Correa1, Ben Creagh-Brown1,2, Simon deLusignan1.   

Abstract

BACKGROUND AND OBJECTIVES: There are limited data about the risk of asthma in people with diabetes. We examined the incidence of asthma in subjects with type 2 diabetes (T2DM) compared to controls, and the association with metformin, sulphonylureas and insulin therapy.
MATERIALS AND METHODS: We conducted a retrospective cohort study using a representative UK primary care database (N = 894 646 adults). We used 1:1 propensity score matching (age, gender, socio-economic deprivation, body mass index and smoking status) to match 29 217 pairs of T2DM cases and controls. We used Cox proportional hazard regression to compare the incidence of asthma in both groups over 8 years of follow-up. In those with T2DM, we used Cox proportional hazard regression to assess for any impact of antidiabetic medications on asthma incidence.
RESULTS: Individuals with T2DM were less likely to develop asthma than matched controls (hazard ratio [HR] 0.85, 95% CI 0.77-0.93). Insulin increased the risk of incident asthma (HR 1.25, 95% CI 1.01-1.56), whilst metformin and sulphonylureas were associated with reduced risk (HR 0.80, 95% CI 0.69-0.93 and HR 0.76, 95% CI 0.60-0.97, respectively). There was no association with diabetes duration, complications or glycaemic control.
CONCLUSIONS: T2DM may have a protective effect against asthma development. Insulin use was associated with an increased risk of asthma, while metformin and sulphonylureas reduced the risk in those with T2DM.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma; computerised medical records; metformin; type 2 diabetes

Year:  2019        PMID: 30815978     DOI: 10.1111/crj.13011

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

Review 1.  Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.

Authors:  Rajeswari Raguraman; Akhil Srivastava; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-08-08       Impact factor: 15.470

2.  Metformin and the Development of Asthma in Patients with Type 2 Diabetes.

Authors:  Fu-Shun Yen; Chih-Cheng Hsu; Ying-Hsiu Shih; Wei-Lin Pan; James Cheng-Chung Wei; Chii-Min Hwu
Journal:  Int J Environ Res Public Health       Date:  2022-07-05       Impact factor: 4.614

3.  Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes.

Authors:  Fu-Shun Yen; Chih-Cheng Hsu; Kai-Chieh Hu; Yu-Tung Hung; Chung Y Hsu; James Cheng-Chung Wei; Chii-Min Hwu
Journal:  Int J Environ Res Public Health       Date:  2022-09-03       Impact factor: 4.614

4.  Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.

Authors:  Dinah Foer; Patrick E Beeler; Jing Cui; Elizabeth W Karlson; David W Bates; Katherine N Cahill
Journal:  Am J Respir Crit Care Med       Date:  2021-04-01       Impact factor: 21.405

5.  Epidemiology and management of atopic dermatitis in England: an observational cohort study protocol.

Authors:  Simon de Lusignan; Helen Alexander; Conor Broderick; John Dennis; Andrew McGovern; Claire Feeney; Carsten Flohr
Journal:  BMJ Open       Date:  2020-09-16       Impact factor: 2.692

6.  The epidemiology of eczema in children and adults in England: A population-based study using primary care data.

Authors:  Simon de Lusignan; Helen Alexander; Conor Broderick; John Dennis; Andrew McGovern; Claire Feeney; Carsten Flohr
Journal:  Clin Exp Allergy       Date:  2020-11-26       Impact factor: 5.018

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.